Blue Cap sees 2026 revenue of EUR 120-140 million

Preliminary 2025 revenue EUR 129.10m, slightly below the EUR 129.60m consensus. Adjusted EBITDA margin improved to 5.5% from 4.9%, and the sale of con-pearl boosted liquidity and equity while enabling a reduction in net financial debt. Blue Cap expects 2026 revenue EUR 120–140m and an adjusted EBITDA margin of 5%–6%, but warned that volatile markets and supply-chain frictions may impact results.

Analysis

Blue Cap's recent liquidity event materially changes the optionality of the holding company: management can either redeploy cash into bolt-on M&A at distressed multiples or accelerate portfolio clean-ups to crystallize embedded value. The market tends to underprice serial acquirers that convert working capital improvements into margin expansion within 12–18 months, creating a path for a re-rate if management executes tidy tuck-ins that are accretive to reported EBITDA.

The operating margin improvement is fragile — it leans heavily on efficiency gains and one-time disposal proceeds rather than secular demand strength. This makes near-term performance highly sensitive to supply-chain shocks and cyclical industrial demand: expect meaningful P&L variance on a 3–9 month horizon if commodity or logistics costs re-accelerate, or if one of the smaller portfolio companies misses stabilization targets.

Consensus appears to treat the balance sheet repair as binary (solved vs unsolved) rather than optionality-rich; that’s the contrarian entry. If management successfully redeploys proceeds into low-single-digit EBITDA multiple assets or continues disciplined deleveraging, upside can be realized quickly; conversely, re-leveraging for aggressive buybacks in a softer macro would cap upside and increase downside. Trade constructs should therefore buy the rerating path while explicitly limiting exposure to a macro-driven earnings rollback.

Key Decisions for Investors

• Long B7EG (Blue Cap) equity — 12 month target +30%, stop -15%. Rationale: buy optionality on further accretive M&A / continued deleveraging; cap position sizing to 2% of fund NAV given execution risk.
• Defined-risk long via B7EG call spread (buy Jan 2027 calls / sell Jan 2027 higher strike) — cost-limited; target 3x premium if company completes 1–2 bolt-on deals or posts upgraded margins. Use this if balance-sheet exposure is undesirable but upside rerate is attractive.
• Relative-value pair: Long B7EG / Short APP (1:1 notional) — 6–12 months. This expresses value-accretion/turnaround vs growth multiple compression risk in adtech; expect 20–40% relative outperformance if execution occurs and macro stays stable.
• Hedge: Buy 3–6 month puts on a European industrials ETF (or long-tail single-stock puts) to protect against a macro-driven earnings rollback — allocate <0.5% NAV. This caps portfolio downside from supply-chain or commodity shocks that would reverse the margin narrative.